Recently, addition of the anti-EGFR antibody cetuximab to gemcitabine plus oxaliplatin did not enhance the efficacy of chemotherapy in patients with advanced biliary tract cancers in a randomized phase II trial [8, 11]. This evidence concerns the gene EGFR and biliary tract cancer.